Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatmen...
Uloženo v:
| Vydáno v: | Haematologica (Roma) Ročník 100; číslo 7; s. 935 - 944 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Italy
Ferrata Storti Foundation
01.07.2015
|
| Témata: | |
| ISSN: | 0390-6078, 1592-8721, 1592-8721 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348. |
|---|---|
| AbstractList | Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348.Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348. Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348. Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable differences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assessment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the study was to reliably identify low amounts of residual leukemic cells against the complex background of regeneration, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consistently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be successfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002 clinical trial information: NCT00114348 |
| Author | Henze, G. Buldini, B. von Stackelberg, A. Seeger, K. Dworzak, M. Karawajew, L. Rhein, P. Eckert, C. Hrusak, O. Ludwig, W.-D. Basso, G. Mejstrikova, E. Gaipa, G. Ratei, R. |
| AuthorAffiliation | 2 St. Anna Children’s Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria 1 Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany 3 Robert-Roessle-Clinic in the HELIOS Klinikum Berlin, Germany 5 Laboratory of Pediatric Onco-Hematology, Department of Pediatrics, University Hospital of Padova, Italy 6 Department of Pediatric Hematology and Oncology, Charles University 2 nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic 4 Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy |
| AuthorAffiliation_xml | – name: 2 St. Anna Children’s Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria – name: 5 Laboratory of Pediatric Onco-Hematology, Department of Pediatrics, University Hospital of Padova, Italy – name: 1 Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany – name: 4 Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy – name: 3 Robert-Roessle-Clinic in the HELIOS Klinikum Berlin, Germany – name: 6 Department of Pediatric Hematology and Oncology, Charles University 2 nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic |
| Author_xml | – sequence: 1 givenname: L. surname: Karawajew fullname: Karawajew, L. – sequence: 2 givenname: M. surname: Dworzak fullname: Dworzak, M. – sequence: 3 givenname: R. surname: Ratei fullname: Ratei, R. – sequence: 4 givenname: P. surname: Rhein fullname: Rhein, P. – sequence: 5 givenname: G. surname: Gaipa fullname: Gaipa, G. – sequence: 6 givenname: B. surname: Buldini fullname: Buldini, B. – sequence: 7 givenname: G. surname: Basso fullname: Basso, G. – sequence: 8 givenname: O. surname: Hrusak fullname: Hrusak, O. – sequence: 9 givenname: W.-D. surname: Ludwig fullname: Ludwig, W.-D. – sequence: 10 givenname: G. surname: Henze fullname: Henze, G. – sequence: 11 givenname: K. surname: Seeger fullname: Seeger, K. – sequence: 12 givenname: A. surname: von Stackelberg fullname: von Stackelberg, A. – sequence: 13 givenname: E. surname: Mejstrikova fullname: Mejstrikova, E. – sequence: 14 givenname: C. surname: Eckert fullname: Eckert, C. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26001791$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkFv1DAQhS1URLeFf4CQj1yy2I4dOxyQUAWlUhEXOFuOPdm4OPFiO0X592S7bUU5cLLlee-bGfmdoZMpToDQa0q2dc34u8HAaEoMW0Yo31LaSCKfoQ0VLauUZPQEbUjdkqohUp2is5xvCGGkbeULdMoaQqhs6Qalr37yowk4QfZuXi_OZzAZsJlMWLLPuFsw-N1QKhtDTLgP8Te2S4kjlLRgP63WYPYZHLaDD26I0WFj5wI4LON-iF0wuXiLA8w_YfTmJXrem5Dh1f15jn58_vT94kt1_e3y6uLjdWW55KVyVtUdd8ww21HV1zW0nDrrXAOEKSYlZ5aIVSGF6MDyRjbOtp1ohOCs5qI-R1dHrovmRu_TumZadDRe3z3EtNMmrYMF0LLlnem5smAFB6daBpZyoD0T0DcCVtaHI2s_dyM4C1NJJjyBPq1MftC7eKs5Vw1jagW8vQek-GuGXPTos4UQzARxzpo2bU2VEoSv0jd_93ps8vBpq4AfBTbFnBP0jxJK9CEb-iEb-pANfczGanv_j836YoqPh4l9-L_5D4gfxcI |
| CitedBy_id | crossref_primary_10_1002_cyto_a_24790 crossref_primary_10_1111_bjh_14310 crossref_primary_10_4102_sajo_v3i0_76 crossref_primary_10_1016_j_transci_2019_08_025 crossref_primary_10_1097_MPH_0000000000000679 crossref_primary_10_1002_cyto_a_23148 crossref_primary_10_3390_ijms17081316 crossref_primary_10_1002_cyto_a_23901 crossref_primary_10_1016_j_jim_2017_11_007 crossref_primary_10_1002_pbc_29990 crossref_primary_10_1016_j_jmoldx_2022_04_013 crossref_primary_10_1007_s12185_017_2206_4 crossref_primary_10_1093_ajcp_aqaa007 crossref_primary_10_3897_folmed_65_e96440 crossref_primary_10_1038_s41375_018_0039_7 crossref_primary_10_1038_s41409_021_01231_y crossref_primary_10_1111_ijlh_14053 crossref_primary_10_3390_diagnostics13010021 crossref_primary_10_1182_blood_2016_07_726307 crossref_primary_10_1080_01496395_2020_1835983 crossref_primary_10_1111_ijlh_13463 crossref_primary_10_1097_MPH_0000000000000624 crossref_primary_10_3390_cancers13236148 crossref_primary_10_1111_bjh_14682 crossref_primary_10_1111_ijlh_12835 crossref_primary_10_1158_1078_0432_CCR_16_2392 crossref_primary_10_1016_j_leukres_2018_03_001 crossref_primary_10_3389_fimmu_2022_949140 crossref_primary_10_5858_arpa_2022_0172_OA crossref_primary_10_1111_ejh_14102 crossref_primary_10_1007_s12288_017_0822_z crossref_primary_10_1055_s_0043_1766137 crossref_primary_10_1016_j_jfma_2016_12_002 crossref_primary_10_1080_10428194_2021_1992755 crossref_primary_10_1016_j_leukres_2020_106491 crossref_primary_10_1080_14737159_2018_1504680 crossref_primary_10_3390_cancers14174169 |
| ContentType | Journal Article |
| Copyright | Copyright© Ferrata Storti Foundation. Copyright© Ferrata Storti Foundation 2015 |
| Copyright_xml | – notice: Copyright© Ferrata Storti Foundation. – notice: Copyright© Ferrata Storti Foundation 2015 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3324/haematol.2014.116707 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1592-8721 |
| EndPage | 944 |
| ExternalDocumentID | oai_doaj_org_article_794baf48cec54ed892ec14e1f25ef65e PMC4486228 26001791 10_3324_haematol_2014_116707 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 29I 2WC 53G 5GY 5RE 5VS AAFWJ AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW CITATION CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ H13 HYE KQ8 OK1 OVT P2P RHI RNS RPM SJN TFS TR2 W8F WOQ WOW C1A CGR CUY CVF ECM EIF NPM UDS 7X8 5PM |
| ID | FETCH-LOGICAL-c474t-dc83b4d2a2cb18f33e941dcdd6e02827742c05b4d755bec4676dc9b5655423453 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 55 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000361196400024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0390-6078 1592-8721 |
| IngestDate | Fri Oct 03 12:42:39 EDT 2025 Tue Sep 30 15:40:12 EDT 2025 Fri Jul 11 12:27:42 EDT 2025 Mon Jul 21 05:54:13 EDT 2025 Sat Nov 29 06:32:39 EST 2025 Tue Nov 18 21:37:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | Copyright© Ferrata Storti Foundation. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-dc83b4d2a2cb18f33e941dcdd6e02827742c05b4d755bec4676dc9b5655423453 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://doaj.org/article/794baf48cec54ed892ec14e1f25ef65e |
| PMID | 26001791 |
| PQID | 1693188504 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_794baf48cec54ed892ec14e1f25ef65e pubmedcentral_primary_oai_pubmedcentral_nih_gov_4486228 proquest_miscellaneous_1693188504 pubmed_primary_26001791 crossref_primary_10_3324_haematol_2014_116707 crossref_citationtrail_10_3324_haematol_2014_116707 |
| PublicationCentury | 2000 |
| PublicationDate | 20150701 |
| PublicationDateYYYYMMDD | 2015-07-01 |
| PublicationDate_xml | – month: 7 year: 2015 text: 20150701 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | Italy |
| PublicationPlace_xml | – name: Italy |
| PublicationTitle | Haematologica (Roma) |
| PublicationTitleAlternate | Haematologica |
| PublicationYear | 2015 |
| Publisher | Ferrata Storti Foundation |
| Publisher_xml | – name: Ferrata Storti Foundation |
| References | 23265714 - Eur J Cancer. 2013 Apr;49(6):1346-55 22945774 - Leukemia. 2013 Mar;27(3):635-41 23666694 - Methods Mol Biol. 2013;999:123-36 12886244 - Leukemia. 2003 Aug;17(8):1566-72 18311775 - Genes Chromosomes Cancer. 2008 Jun;47(6):471-80 19377076 - Haematologica. 2009 Jun;94(6):870-4 11675066 - Lancet. 2001 Oct 13;358(9289):1239-41 21487112 - Blood. 2011 Jun 9;117(23):6267-76 15295608 - Leukemia. 2004 Oct;18(10):1630-6 15356653 - Leukemia. 2004 Oct;18(10):1727-8; author reply 1728-9 11480560 - Leukemia. 2001 Aug;15(8):1185-92 9718378 - N Engl J Med. 1998 Aug 27;339(9):591-8 15538405 - Leukemia. 2005 Jan;19(1):49-56 19805690 - J Clin Oncol. 2009 Nov 1;27(31):5168-74 14981525 - Leukemia. 2004 Mar;18(3):499-504 15384977 - Br J Haematol. 2004 Oct;127(1):50-8 18565891 - J Clin Oncol. 2008 Jun 20;26(18):3046-50 18024872 - J Clin Oncol. 2007 Nov 20;25(33):5254-61 11694770 - Onkologie. 2001 Oct;24(5):442-8 9264380 - Leukemia. 1997 Aug;11(8):1266-73 17287857 - Leukemia. 2007 Apr;21(4):706-13 20201055 - Cytometry B Clin Cytom. 2010 May;78(3):147-53 18388178 - Blood. 2008 Jun 15;111(12):5477-85 18754029 - Leukemia. 2008 Dec;22(12):2193-200 20228269 - Blood. 2010 May 6;115(18):3763-71 18548617 - Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 18780832 - Blood. 2008 Nov 15;112(10):3982-8 2868172 - Lancet. 1986 Feb 8;1(8476):307-10 15029212 - Leukemia. 2004 May;18(5):934-8 22525580 - Curr Opin Hematol. 2012 Jul;19(4):313-8 11877265 - Blood. 2002 Mar 15;99(6):1952-8 20154213 - Blood. 2010 Apr 22;115(16):3206-14 10086733 - Leukemia. 1999 Mar;13(3):419-27 23070018 - Leukemia. 2013 Feb;27(2):370-6 18239620 - Leukemia. 2008 Apr;22(4):771-82 19212338 - Leukemia. 2009 Jun;23(6):1073-9 18711187 - J Clin Oncol. 2008 Aug 20;26(24):3971-8 14607753 - Haematologica. 2003 Nov;88(11):1245-52 10673751 - Leukemia. 2000 Feb;14(2):316-23 22581001 - Haematologica. 2012 Oct;97(10):1582-93 20467922 - Curr Hematol Malig Rep. 2010 Jul;5(3):169-76 23775972 - J Clin Oncol. 2013 Jul 20;31(21):2736-42 11236945 - Leukemia. 2001 Feb;15(2):278-9 20535816 - Pediatr Blood Cancer. 2010 Dec 15;55(7):1287-95 18669463 - J Clin Oncol. 2008 Aug 1;26(22):3756-62 23757107 - Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69 24097105 - Curr Opin Oncol. 2013 Nov;25(6):701-6 17330098 - Leukemia. 2007 May;21(5):897-905 11069029 - Leukemia. 2000 Nov;14(11):1939-43 17485550 - Blood. 2007 Sep 1;110(5):1607-11 |
| References_xml | – reference: 15384977 - Br J Haematol. 2004 Oct;127(1):50-8 – reference: 19805690 - J Clin Oncol. 2009 Nov 1;27(31):5168-74 – reference: 20201055 - Cytometry B Clin Cytom. 2010 May;78(3):147-53 – reference: 11694770 - Onkologie. 2001 Oct;24(5):442-8 – reference: 18754029 - Leukemia. 2008 Dec;22(12):2193-200 – reference: 24097105 - Curr Opin Oncol. 2013 Nov;25(6):701-6 – reference: 11069029 - Leukemia. 2000 Nov;14(11):1939-43 – reference: 23265714 - Eur J Cancer. 2013 Apr;49(6):1346-55 – reference: 23775972 - J Clin Oncol. 2013 Jul 20;31(21):2736-42 – reference: 23757107 - Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69 – reference: 21487112 - Blood. 2011 Jun 9;117(23):6267-76 – reference: 15029212 - Leukemia. 2004 May;18(5):934-8 – reference: 15538405 - Leukemia. 2005 Jan;19(1):49-56 – reference: 17330098 - Leukemia. 2007 May;21(5):897-905 – reference: 20154213 - Blood. 2010 Apr 22;115(16):3206-14 – reference: 18024872 - J Clin Oncol. 2007 Nov 20;25(33):5254-61 – reference: 18388178 - Blood. 2008 Jun 15;111(12):5477-85 – reference: 10086733 - Leukemia. 1999 Mar;13(3):419-27 – reference: 11675066 - Lancet. 2001 Oct 13;358(9289):1239-41 – reference: 2868172 - Lancet. 1986 Feb 8;1(8476):307-10 – reference: 18548617 - Cytometry B Clin Cytom. 2008 Nov;74(6):331-40 – reference: 18780832 - Blood. 2008 Nov 15;112(10):3982-8 – reference: 18669463 - J Clin Oncol. 2008 Aug 1;26(22):3756-62 – reference: 20467922 - Curr Hematol Malig Rep. 2010 Jul;5(3):169-76 – reference: 22945774 - Leukemia. 2013 Mar;27(3):635-41 – reference: 17287857 - Leukemia. 2007 Apr;21(4):706-13 – reference: 20228269 - Blood. 2010 May 6;115(18):3763-71 – reference: 19377076 - Haematologica. 2009 Jun;94(6):870-4 – reference: 14607753 - Haematologica. 2003 Nov;88(11):1245-52 – reference: 18239620 - Leukemia. 2008 Apr;22(4):771-82 – reference: 18565891 - J Clin Oncol. 2008 Jun 20;26(18):3046-50 – reference: 11480560 - Leukemia. 2001 Aug;15(8):1185-92 – reference: 18711187 - J Clin Oncol. 2008 Aug 20;26(24):3971-8 – reference: 9264380 - Leukemia. 1997 Aug;11(8):1266-73 – reference: 23666694 - Methods Mol Biol. 2013;999:123-36 – reference: 11877265 - Blood. 2002 Mar 15;99(6):1952-8 – reference: 22581001 - Haematologica. 2012 Oct;97(10):1582-93 – reference: 23070018 - Leukemia. 2013 Feb;27(2):370-6 – reference: 10673751 - Leukemia. 2000 Feb;14(2):316-23 – reference: 15295608 - Leukemia. 2004 Oct;18(10):1630-6 – reference: 14981525 - Leukemia. 2004 Mar;18(3):499-504 – reference: 11236945 - Leukemia. 2001 Feb;15(2):278-9 – reference: 12886244 - Leukemia. 2003 Aug;17(8):1566-72 – reference: 15356653 - Leukemia. 2004 Oct;18(10):1727-8; author reply 1728-9 – reference: 9718378 - N Engl J Med. 1998 Aug 27;339(9):591-8 – reference: 17485550 - Blood. 2007 Sep 1;110(5):1607-11 – reference: 22525580 - Curr Opin Hematol. 2012 Jul;19(4):313-8 – reference: 18311775 - Genes Chromosomes Cancer. 2008 Jun;47(6):471-80 – reference: 20535816 - Pediatr Blood Cancer. 2010 Dec 15;55(7):1287-95 – reference: 19212338 - Leukemia. 2009 Jun;23(6):1073-9 |
| SSID | ssj0020997 |
| Score | 2.3892436 |
| Snippet | Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating minimal residual disease in treatment... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 935 |
| SubjectTerms | Antigens, CD - genetics Antigens, CD - immunology Antineoplastic Agents - therapeutic use B-Lymphocytes - drug effects B-Lymphocytes - immunology B-Lymphocytes - pathology Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology Bone Marrow - drug effects Bone Marrow - immunology Bone Marrow - pathology Child, Preschool DNA Nucleotidylexotransferase - genetics DNA Nucleotidylexotransferase - immunology Flow Cytometry - methods Gene Expression Humans Immunophenotyping Infant Neoplasm, Residual Polymerase Chain Reaction Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - immunology Recurrence |
| Title | Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/26001791 https://www.proquest.com/docview/1693188504 https://pubmed.ncbi.nlm.nih.gov/PMC4486228 https://doaj.org/article/794baf48cec54ed892ec14e1f25ef65e |
| Volume | 100 |
| WOSCitedRecordID | wos000361196400024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: DOA dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BhRAXBC3Q8KiMhLiFbhI7cY4FUXGgFQeQ9hb5MVEjdpMqmwXl3zOTx2oXIfXCNfFLnrHnG4_nM8A7sqlaYxKFuSnjUGJmQk12MszJ-FurIudHEtev2fW1Xi7zb3tPffGdsJEeeJy4c9IXa0qpHTol0es8RhdJjMpYYZkq5N13keWzMzW5WpwPOsQPcnKOyAqOSXMJoYfzG8NkqA2HHSL5gcMQ_JTsnlEauPv_BTj_vje5Z4gun8DjCUGKi3HkT-Ee1sdwclFTb-tevBfDnc7hsPwYHl5NofMTaK-qulpTRfKvhwQsMcVmhJl4SYTtxXBQGjKTdSvKVfNbuJ6axa7tRVULTny53aAXbiZEFsZtOxSrnpSisYTEaVBihdufuK7MM_hx-fn7py_h9OBC6GQmu9A7nVjpYxM7G-kySZBE5p33KbJrRkgxdgtFJTKlSPa0x6be5ZYwoSJUJlXyHI7qpsZTEGW-sIQkck-tEeYxhpBQFNvUkzBSLU0AyTzjhZvYyPlRjFVBXgnLqZjlVLCcilFOAYS7WrcjG8cd5T-yMHdlmUt7-EAaVkwaVtylYQG8nVWhoLXHARVTY7PdFExkE2mtFjKAF6Nq7Lpi4n-mfg0gO1Cag7Ec_qmrm4HfmzzmNI71y_8x-FfwiOZDjReMX8NR127xDTxwv7pq057B_Wypz4al8wc28yAe |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Minimal+residual+disease+analysis+by+eight-color+flow+cytometry+in+relapsed+childhood+acute+lymphoblastic+leukemia&rft.jtitle=Haematologica+%28Roma%29&rft.au=Karawajew%2C+Leonid&rft.au=Dworzak%2C+Michael&rft.au=Ratei%2C+Richard&rft.au=Rhein%2C+Peter&rft.date=2015-07-01&rft.issn=1592-8721&rft.eissn=1592-8721&rft.volume=100&rft.issue=7&rft.spage=935&rft_id=info:doi/10.3324%2Fhaematol.2014.116707&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |